Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Ulf Stendahl"'
Publikováno v:
Acta Oncologica. 49:812-815
Background. The human leucine-rich repeats and immunoglobulin-like domains (LRIG) protein family comprises LRIG1, 2, and 3. LRIG1 negatively regulates growth factor signaling and is a proposed tumor suppressor. In early stage uterine cervical carcino
Publikováno v:
Gynecologic Oncology. 112:235-240
OBJECTIVES: To study if immunohistochemical expression of tumor markers as prognostic predictors is influenced by clinical stage, adjustments for expression of other tumor markers and histological type in cervical cancer. METHODS: The study included
Autor:
K Ekman, Håkan Hedman, Annika Lindström, Ulf Stendahl, Tibor Tot, Dan Hellberg, Roger Henriksson
Publikováno v:
International Journal of Gynecologic Cancer. 18:312-317
The aim is to evaluate LRIG1 as a prognosis predictor and correlations to cofactors in squamous cell cervical cancer. LRIG1 expression was studied in 128 cervical carcinomas and was compared with expression of nine other tumor markers. Smoking histor
Autor:
Ingrid Mogren, Ulf Stendahl, Olga Nagaeva, Vladimir Baranov, Lucia Mincheva-Nilsson, Jenny Hernestål, Ting Chen, Julia Antsiferova
Publikováno v:
The Journal of Immunology. 176:3585-3592
Mammalian pregnancy is an intriguing immunological phenomenon where the semiallogeneic fetus is not rejected. Tolerance toward the fetus involves a number of mechanisms associated with modifications of the immune status of the mother. In this study,
Autor:
Ulf Stendahl, Sonia Andersson, Tord Ångström, Keng-Ling Wallin, Gert Auer, Ann-Cathrin Hellström
Publikováno v:
International Journal of Gynecological Cancer. 15:1065-1072
Carcinoma of the uterine cervix is one of the most prevalent malignancies among women in developing countries and the third most common type worldwide. Squamous cell carcinoma predominates in the cervix uteri, while adenocarcinoma and adenosquamous c
Autor:
Ulf Stendahl, Tord Ångström, Björn Zackrisson, Taina Turpeenniemi-Hujanen, Ulla Puistola, Marita Rauvala, Kristina Aglund
Publikováno v:
Gynecologic Oncology. 94:699-704
Matrix metalloproteinases (MMPs) have been linked to aggressive behavior in several malignancies. Gelatinases (MMP-2 and MMP-9) in particular are prognostic factors in many adeno- and epithelial cancers. However, no conclusive data exist concerning t
Autor:
Anju Zhang, Ulf Stendahl, Tord Ångström, Keng-Ling Wallin, Susanne Månér, Regina C. Betz, Frank Bergman, Anders Zetterberg
Publikováno v:
International Journal of Cancer. 101:427-433
The development of cervical carcinoma is closely associated with HPV infection. However, other genetic alterations also play an important role. In this study, we analyzed copy number alterations of several oncogene loci in a panel of 84 cervical tumo
Autor:
Göran Hallmans, Tarja Anttila, Irma Ikäheimo, Matti Lehtinen, Jorma Paavonen, Joakim Dillner, Tord Ångström, Keng-Ling Wallin, Tapio Luostarinen, Frank Bergman, Pentti Koskela, Fredrik Wiklund, Ulf Stendahl
Publikováno v:
International Journal of Cancer. 101:371-374
Persistent human papillomavirus (HPV) infection is an established cause of cervical cancer, but the role of other sexually transmitted agents, most notably Chlamydia trachomatis, has not been well defined. The women participating in the population-ba
Autor:
Kathrin U. Jansen, Amha Tadesse, Michael Pawlita, Klaus Zumbach, Joakim Dillner, Ulf Stendahl, Ilvars Silins, Bo Frankendal, Per Lenner, Elisabeth Åvall-Lundqvist
Publikováno v:
Gynecologic Oncology. 85:333-338
We wished to evaluate whether the presence of antibodies to HPV or to the HPV oncoproteins E6 and E7 or type of HPV DNA is related to prognosis among cervical cancer patients.Blood samples were drawn from 313 patients with incident, untreated cervica
Autor:
Håkan Andersson, Bengt Sorbe, Birgitta Petterson, Bertil Westholm, Anna Himmelman, György Horvath, Thomas Högberg, Marianne Ryberg, Elisabeth Björkholm, Ulf Stendahl, Helena Persson, Bo Frankendal, Ernst Simonsen, Claes G. Tropé
Publikováno v:
Acta Oncologica. 35:109-118
In a controlled prospective randomized study the regimen doxorubicin (A) 40 mg/m2 + melphalan (M) 0.4 mg/kg was compared with A + M + cisplatin (C) 50 mg/m2 given every four weeks in advanced ovarian cancer, FIGO stage III or IV and with serous or an